ABTAbbott Laboratories
Is it growing?
Growth is fading: earnings down −61% year on year and operating margin narrowing (−1.6 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +3% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 15.8% now against 17.4% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is ABT growing?
Abbott Laboratories's revenue has grown 5.0% a year over three years, and grown 3.0% a year over five, with earnings per share compounding at 1.9%.
Revenue growth, 3-year annual rate · Medical Devices median +11% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +3.0%
Revenue growth, 5-year rate · +5.0% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- +1.9%
Earnings per share, 3-year rate · revenue +5.0% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 19
Years of annual history on file · FY2007 to FY2025, as filed
Details›
- Revenue FY2021
- $43.1B
- Revenue FY2022
- $43.7B
- Revenue FY2023
- $40.1B
- Revenue FY2024
- $42.0B
- Revenue FY2025
- $44.3B
Annual income statements as filed with the SEC.
Medical Devices
The closest names by size in the same industry